Archives
ADA: Once-Daily Orforglipron Linked to Significant Weight Reduction
Weight reduction of at least 10 percent occurred in 46 to 75 percent receiving orforglipron by week 36
ADA: Glycemic Control Up With Weekly Icodec Versus Daily Insulin Glargine
Findings in adults with type 2 diabetes who had not previously received insulin
Continuous Meropenem No Benefit in Critically Ill Patients With Sepsis
No improvement seen in composite of all-cause mortality and emergence of pandrug- or extensively drug-resistant bacteria
ENDO: Testosterone-Replacement Noninferior to Placebo for Cardiovascular Events
Findings seen in middle-aged men with preexisting or high risk of cardiovascular disease and hypogonadism
Successful Intubation on First Attempt Improved With Video Laryngoscopy
Findings seen for critically ill adults undergoing tracheal intubation
Lower Mortality Seen With Hemodiafiltration for Kidney Failure
Risk for death from any cause reduced with hemodiafiltration versus hemodialysis among patients with kidney failure
ENDO: Cases of Gestational Diabetes Increased During Pandemic
Progressive sociodemographic changes and gestational weight gain do not fully explain increased risk seen during the second year of the pandemic
Tranexamic Acid Does Not Up Functional Outcome After Major Trauma
No improvement seen in favorable functional outcome at six months, but reduced risk of death at 28 days after injury
Athlete Awareness of Sudden Cardiac Arrest Low
Furthermore, only half of athletes report receiving cardiopulmonary resuscitation training
Letermovir Noninferior for CMV Prophylaxis in Kidney Recipients
Findings in cytomegalovirus-seronegative kidney transplant recipients who receive organ from cytomegalovirus-seropositive donors
